2-[[(2S)-2-[(4-bromo-2-fluoro-phenyl)carbamoylamino]-4-methyl-pentanoyl]amino]acetic acid

ID: ALA5285150

Max Phase: Preclinical

Molecular Formula: C15H19BrFN3O4

Molecular Weight: 404.24

Names and Identifiers

Canonical SMILES:  CC(C)C[C@H](NC(=O)Nc1ccc(Br)cc1F)C(=O)NCC(=O)O

Standard InChI:  InChI=1S/C15H19BrFN3O4/c1-8(2)5-12(14(23)18-7-13(21)22)20-15(24)19-11-4-3-9(16)6-10(11)17/h3-4,6,8,12H,5,7H2,1-2H3,(H,18,23)(H,21,22)(H2,19,20,24)/t12-/m0/s1

Standard InChI Key:  GWOULRCUFTYSHG-LBPRGKRZSA-N

Molfile:  

 
     RDKit          2D

 24 24  0  0  0  0  0  0  0  0999 V2000
   -3.5569    0.4104    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5569   -0.4145    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8435   -0.8209    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1364   -0.4108    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1364    0.4108    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8453    0.8210    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4247    0.8217    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7130    0.4108    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0013    0.8217    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.7103    0.4108    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4219    0.8217    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4219    1.6435    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.1336    0.4108    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.8453    0.8217    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5570    0.4108    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2686    0.8217    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.5570   -0.4108    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.7103   -0.4108    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4219   -0.8218    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4219   -1.6435    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1336   -0.4108    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7130   -0.4108    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2686   -0.8254    0.0000 Br  0  0  0  0  0  0  0  0  0  0  0  0
   -1.4247   -0.8218    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  1  2  0
  5  7  1  0
  7  8  1  0
  8  9  1  0
 10  9  1  6
 10 11  1  0
 11 12  2  0
 11 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 15 17  2  0
 10 18  1  0
 18 19  1  0
 19 20  1  0
 19 21  1  0
  8 22  2  0
  2 23  1  0
  4 24  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5285150

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 404.24

Molecular Weight (Monoisotopic): 403.0543

AlogP: 2.33

#Rotatable Bonds: 7

Polar Surface Area: 107.53

Molecular Species: ACID

HBA: 3

HBD: 4

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 4

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 3.55

CX Basic pKa: ┄

CX LogP: 2.21

CX LogD: -1.15

Aromatic Rings: 1

Heavy Atoms: 24

QED Weighted: 0.56

Np Likeness Score: -1.27

References

1. Maciuszek M, Cacace A, Brennan E, Godson C, Chapman TM..  (2021)  Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential.,  213  [PMID:33486199] [10.1016/j.ejmech.2021.113167]

Source

Source(1):

• Scientific Literature